Symbols / AMPH Stock $17.64 -3.74% Amphastar Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
AMPH (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Yongfeng Zhang Ph.D.
Exch · Country NMS · United States
Market Cap 777.58M
Enterprise Value 1.20B
Income 79.23M
Sales 720.53M
FCF (ttm) 103.10M
Book/sh 17.33
Cash/sh 6.62
Employees 1,976
Insider 10d —
IPO Jun 25, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 10.62
Forward P/E 5.35
PEG —
P/S 1.08
P/B 1.02
P/C —
EV/EBITDA 6.09
EV/Sales 1.67
Quick Ratio 2.73
Current Ratio 3.85
Debt/Eq 88.75
LT Debt/Eq —
EPS (ttm) 1.66
EPS next Y 3.30
EPS Growth -72.50%
Revenue Growth 0.40%
EPS Gr Q/Q -74.60%
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA 5.34%
ROE 10.39%
ROIC —
Gross Margin 47.34%
Oper. Margin 7.96%
Profit Margin 11.00%
Shs Outstand 44.09M
Shs Float 32.84M
Insider Own 29.63%
Instit Own 80.36%
Short Float 16.67%
Short Ratio 8.20
Short Interest 3.59M
52W High 31.26
vs 52W High -43.59%
52W Low 17.03
vs 52W Low 3.55%
Beta 0.97
Impl. Vol. 1.39%
Rel Volume 0.47
Avg Volume 592.30K
Volume 279.38K
Target (mean) $25.17
Tgt Median $24.00
Tgt Low $21.00
Tgt High $30.00
# Analysts 6
Recom Hold
Prev Close $18.32
Price $17.64
Change -3.74%
About

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$25.17
Mean price target
2. Current target
$17.64
Latest analyst target
3. DCF / Fair value
$42.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$17.64
Low
$21.00
High
$30.00
Mean
$25.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-14 down Wells Fargo Overweight → Equal-Weight $19
2026-05-11 reit Piper Sandler Neutral → Neutral $21
2026-05-08 down Needham Buy → Hold —
2026-04-21 down Jefferies Buy → Hold $22
2026-04-08 main Barclays Equal-Weight → Equal-Weight $23
2026-02-27 main Wells Fargo Overweight → Overweight $30
2026-02-27 main Needham Buy → Buy $30
2025-12-09 init Barclays — → Equal-Weight $30
2025-11-07 main Needham Buy → Buy $34
2025-10-22 reit Needham Buy → Buy $36
2025-08-26 main B of A Securities Neutral → Neutral $32
2025-08-12 up Needham Hold → Buy $36
2025-08-08 main Piper Sandler Neutral → Neutral $25
2025-05-12 down JP Morgan Overweight → Neutral $30
2025-05-08 main Wells Fargo Overweight → Overweight $35
2025-04-10 reit Needham Hold → Hold —
2025-03-21 main Piper Sandler Neutral → Neutral $32
2025-02-04 down Piper Sandler Overweight → Neutral $36
2024-11-22 init Wells Fargo — → Overweight $55
2024-08-08 reit Needham — → Hold —
News
RSS: Latest AMPH news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-09 ZHOU RONG Officer — 39,432 $0.00 $0
2026-03-09 LIAWATIDEWI YAKOB Officer and Director — 35,450 $0.00 $0
2026-03-09 PETERS WILLIAM J Chief Financial Officer — 58,693 $0.00 $0
2026-03-09 ZHANG JACK YONGFENG Chief Executive Officer — 252,966 $0.00 $0
2025-12-17 ZHOU RONG Officer — 9,787 $26.20 $256,379
2025-12-17 ZHOU RONG Officer — 9,787 $11.33 $110,887
2025-12-12 PETERSEN FLOYD F Director — 4,163 $25.69 $107,508
2025-11-25 PRINS RICHARD K Director — 4,179 $27.10 $113,253
2025-11-25 PRINS RICHARD K Director — 4,179 $16.69 $69,748
2025-11-13 PETERSEN FLOYD F Director — 16,679 $26.49 $441,837
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
719.89
-1.65%
731.97
+13.59%
644.39
+29.14%
498.99
Operating Revenue
719.89
+0.99%
712.81
+20.16%
593.24
+18.89%
498.99
Cost Of Revenue
363.83
+1.60%
358.11
+22.11%
293.27
+17.25%
250.13
Reconciled Cost Of Revenue
363.83
+1.60%
358.11
+22.11%
293.27
+17.25%
250.13
Gross Profit
356.06
-4.76%
373.86
+6.47%
351.12
+41.09%
248.86
Operating Expense
215.65
+28.03%
168.44
+9.28%
154.13
+9.03%
141.36
Research And Development
85.84
+16.14%
73.91
+0.23%
73.74
-1.38%
74.77
Selling General And Administration
129.81
+37.33%
94.52
+17.57%
80.39
+20.72%
66.59
Selling And Marketing Expense
43.88
+16.09%
37.80
+31.02%
28.85
+34.01%
21.53
General And Administrative Expense
85.92
+51.49%
56.72
+10.05%
51.54
+14.38%
45.06
Other Gand A
85.92
+51.49%
56.72
+10.05%
51.54
+14.38%
45.06
Total Expenses
579.48
+10.05%
526.55
+17.69%
447.41
+14.28%
391.49
Operating Income
140.40
-31.65%
205.42
+4.28%
196.99
+83.25%
107.50
Total Operating Income As Reported
140.40
-31.65%
205.42
+4.28%
196.99
+83.25%
107.50
EBITDA
212.31
-23.44%
277.31
+15.41%
240.29
+64.40%
146.16
Normalized EBITDA
212.31
-23.44%
277.31
+15.41%
240.29
+64.40%
146.16
Reconciled Depreciation
63.20
+10.48%
57.20
+36.93%
41.78
+47.75%
28.27
EBIT
149.10
-32.26%
220.11
+10.88%
198.52
+68.40%
117.89
Net Income
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Pretax Income
123.62
-34.85%
189.76
+10.74%
171.36
+47.67%
116.04
Net Non Operating Interest Income Expense
-16.80
+14.84%
-19.73
+9.07%
-21.70
-4033.14%
-0.53
Interest Expense Non Operating
25.48
-16.02%
30.34
+11.73%
27.16
+1371.18%
1.85
Net Interest Income
-16.80
+14.84%
-19.73
+9.07%
-21.70
-4033.14%
-0.53
Interest Expense
25.48
-16.02%
30.34
+11.73%
27.16
+1371.18%
1.85
Interest Income Non Operating
8.68
-18.22%
10.61
+94.39%
5.46
+313.25%
1.32
Interest Income
8.68
-18.22%
10.61
+94.39%
5.46
+313.25%
1.32
Other Income Expense
0.02
-99.44%
4.08
+203.74%
-3.93
-143.33%
9.07
Other Non Operating Income Expenses
0.02
-99.44%
4.08
+203.74%
-3.93
-143.33%
9.07
Tax Provision
25.53
-13.96%
29.67
-6.79%
31.83
+35.59%
23.48
Tax Rate For Calcs
0.00
+32.38%
0.00
-15.83%
0.00
-8.04%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Net Income From Continuing Operation Net Minority Interest
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Net Income From Continuing And Discontinued Operation
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Net Income Continuous Operations
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Minority Interests
—
—
0.00
0.00
Normalized Income
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Net Income Common Stockholders
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Diluted EPS
2.03
-33.66%
3.06
+17.69%
2.60
+49.43%
1.74
Basic EPS
2.10
-36.17%
3.29
+15.44%
2.85
+51.60%
1.88
Basic Average Shares
46.74
-3.48%
48.43
+0.34%
48.27
-0.59%
48.55
Diluted Average Shares
48.22
-7.38%
52.06
-1.78%
53.00
+1.09%
52.43
Diluted NI Availto Com Stockholders
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Earnings From Equity Interest Net Of Tax
0.00
+100.00%
-0.57
+71.08%
-1.98
-68.31%
-1.18
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,629.30
+3.29%
1,577.47
+4.27%
1,512.91
+103.90%
741.99
Current Assets
636.02
+19.09%
534.07
+9.08%
489.60
+29.41%
378.32
Cash Cash Equivalents And Short Term Investments
282.81
+27.60%
221.65
-13.69%
256.81
+46.11%
175.76
Cash And Cash Equivalents
170.18
+12.25%
151.61
+5.07%
144.30
-7.56%
156.10
Other Short Term Investments
112.64
+60.82%
70.04
-37.75%
112.51
+472.16%
19.66
Receivables
160.73
+16.44%
138.04
+19.54%
115.47
+29.78%
88.97
Accounts Receivable
143.56
+5.33%
136.29
+18.57%
114.94
+29.43%
88.80
Gross Accounts Receivable
146.86
+5.06%
139.79
+18.72%
117.74
+28.68%
91.50
Allowance For Doubtful Accounts Receivable
-3.30
+5.71%
-3.50
-25.00%
-2.80
-3.70%
-2.70
Taxes Receivable
17.17
+882.66%
1.75
+232.13%
0.53
+207.60%
0.17
Inventory
176.89
+15.06%
153.74
+45.27%
105.83
+2.17%
103.58
Raw Materials
106.83
+31.06%
81.51
+62.76%
50.08
+5.20%
47.61
Work In Process
40.44
+23.27%
32.81
+6.44%
30.82
-16.90%
37.09
Finished Goods
29.62
-24.87%
39.42
+58.14%
24.93
+31.99%
18.89
Prepaid Assets
—
—
—
—
Restricted Cash
2.44
+0.00%
2.44
+0.00%
2.44
+0.00%
2.44
Other Current Assets
13.15
-27.79%
18.21
+101.10%
9.06
+19.75%
7.56
Total Non Current Assets
993.28
-4.80%
1,043.40
+1.96%
1,023.31
+181.39%
363.67
Net PPE
353.72
+2.64%
344.63
+9.18%
315.64
+19.30%
264.57
Gross PPE
659.99
+7.10%
616.21
+9.85%
560.94
+15.75%
484.60
Accumulated Depreciation
-306.27
-12.77%
-271.59
-10.72%
-245.30
-11.48%
-220.03
Properties
0.00
0.00
0.00
0.00
Land And Improvements
7.55
+1.78%
7.42
-0.83%
7.48
+0.44%
7.45
Buildings And Improvements
196.68
+16.08%
169.43
+0.39%
168.77
+29.10%
130.73
Machinery Furniture Equipment
342.10
+9.16%
313.38
+7.53%
291.43
+22.58%
237.74
Construction In Progress
24.41
-33.47%
36.69
+96.43%
18.68
-63.27%
50.84
Other Properties
43.15
-8.73%
47.28
+43.73%
32.90
+25.05%
26.31
Leases
46.10
+9.73%
42.01
+0.78%
41.69
+32.19%
31.54
Goodwill And Other Intangible Assets
565.97
-4.18%
590.66
-3.69%
613.29
+1544.31%
37.30
Goodwill
3.40
+11.58%
3.05
-5.19%
3.22
+2.88%
3.13
Other Intangible Assets
562.56
-4.26%
587.61
-3.68%
610.08
+1685.32%
34.17
Investments And Advances
0.00
-100.00%
11.00
-27.71%
15.21
+530.16%
2.41
Long Term Equity Investment
—
0.00
-100.00%
0.53
-78.17%
2.41
Other Investments
0.00
-100.00%
11.00
-25.12%
14.69
0.00
Non Current Deferred Assets
42.46
-40.30%
71.12
+33.56%
53.25
+38.22%
38.53
Non Current Deferred Taxes Assets
42.46
-40.30%
71.12
+33.56%
53.25
+38.22%
38.53
Other Non Current Assets
31.14
+19.79%
25.99
+0.32%
25.91
+24.23%
20.86
Total Liabilities Net Minority Interest
840.49
-0.55%
845.17
-3.24%
873.49
+309.46%
213.33
Current Liabilities
158.16
-8.98%
173.76
-22.91%
225.41
+137.62%
94.86
Payables And Accrued Expenses
148.59
-10.88%
166.72
-24.58%
221.06
+148.91%
88.81
Payables
32.83
-18.29%
40.18
+48.55%
27.05
+7.88%
25.07
Accounts Payable
32.59
+6.81%
30.51
+19.95%
25.44
+24.08%
20.50
Current Accrued Expenses
115.76
-8.52%
126.54
-34.78%
194.02
+204.38%
63.74
Total Tax Payable
0.24
-97.53%
9.66
+500.62%
1.61
-64.80%
4.57
Income Tax Payable
0.24
-97.53%
9.66
+500.62%
1.61
-64.80%
4.57
Current Debt And Capital Lease Obligation
9.57
+35.96%
7.04
+62.09%
4.34
-28.22%
6.05
Current Debt
1.64
+601.28%
0.23
-46.33%
0.44
-85.69%
3.05
Other Current Borrowings
1.64
+601.28%
0.23
-46.33%
0.44
-85.69%
3.05
Current Capital Lease Obligation
7.93
+16.52%
6.80
+74.19%
3.91
+30.07%
3.00
Total Non Current Liabilities Net Minority Interest
682.34
+1.63%
671.41
+3.60%
648.08
+447.06%
118.47
Long Term Debt And Capital Lease Obligation
646.43
+0.45%
643.51
+3.91%
619.30
+541.54%
96.53
Long Term Debt
608.75
+1.18%
601.63
+2.04%
589.58
+709.43%
72.84
Long Term Capital Lease Obligation
37.68
-10.02%
41.88
+40.91%
29.72
+25.44%
23.69
Non Current Deferred Liabilities
5.93
-14.82%
6.96
+14.69%
6.07
-17.68%
7.37
Non Current Deferred Taxes Liabilities
5.93
-14.82%
6.96
+14.69%
6.07
-17.68%
7.37
Other Non Current Liabilities
29.98
+43.13%
20.95
-7.80%
22.72
+55.98%
14.56
Stockholders Equity
788.80
+7.72%
732.30
+14.53%
639.42
+20.95%
528.66
Common Stock Equity
788.80
+7.72%
732.30
+14.53%
639.42
+20.95%
528.66
Capital Stock
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
61.78
+1.53%
60.85
+2.45%
59.39
+2.20%
58.11
Ordinary Shares Number
45.65
-4.14%
47.62
-0.94%
48.07
-0.09%
48.11
Treasury Shares Number
16.13
+21.96%
13.23
+16.85%
11.32
+13.23%
10.00
Additional Paid In Capital
535.38
+5.93%
505.40
+3.98%
486.06
+6.81%
455.08
Retained Earnings
666.88
+17.25%
568.79
+38.98%
409.27
+50.62%
271.72
Gains Losses Not Affecting Retained Earnings
-5.31
+42.12%
-9.18
-8.29%
-8.48
+1.69%
-8.62
Treasury Stock
408.15
+22.67%
332.71
+34.47%
247.43
+30.55%
189.52
Minority Interest
—
—
—
—
Other Equity Adjustments
-5.31
+42.12%
-9.18
-8.29%
-8.48
+1.69%
-8.62
Total Equity Gross Minority Interest
788.80
+7.72%
732.30
+14.53%
639.42
+20.95%
528.66
Total Capitalization
1,397.55
+4.77%
1,333.93
+8.54%
1,229.00
+104.32%
601.50
Working Capital
477.86
+32.62%
360.31
+36.38%
264.19
-6.80%
283.46
Invested Capital
1,399.19
+4.87%
1,334.16
+8.52%
1,229.44
+103.37%
604.54
Total Debt
656.00
+0.84%
650.55
+4.31%
623.64
+507.94%
102.58
Net Debt
440.21
-2.23%
450.25
+1.02%
445.72
—
Capital Lease Obligations
45.61
-6.31%
48.69
+44.78%
33.63
+25.96%
26.70
Net Tangible Assets
222.84
+57.33%
141.64
+442.13%
26.13
-94.68%
491.36
Tangible Book Value
222.84
+57.33%
141.64
+442.13%
26.13
-94.68%
491.36
Investmentsin Associatesat Cost
—
—
—
2.41
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
156.12
-26.84%
213.39
+16.28%
183.50
+105.76%
89.18
Cash Flow From Continuing Operating Activities
156.12
-26.84%
213.39
+16.28%
183.50
+105.76%
89.18
Net Income From Continuing Operations
98.09
-38.51%
159.52
+15.98%
137.54
+50.51%
91.39
Depreciation Amortization Depletion
63.20
+10.48%
57.20
+36.93%
41.78
+47.75%
28.27
Depreciation
38.15
+17.44%
32.49
+12.23%
28.95
+5.95%
27.32
Amortization Cash Flow
25.05
+1.34%
24.72
+92.66%
12.83
+1244.86%
0.95
Depreciation And Amortization
63.20
+10.48%
57.20
+36.93%
41.78
+47.75%
28.27
Amortization Of Intangibles
25.05
+1.34%
24.72
+92.66%
12.83
+1244.86%
0.95
Other Non Cash Items
3.35
-44.38%
6.03
-47.08%
11.40
+2346.14%
0.47
Stock Based Compensation
27.28
+11.94%
24.37
+20.38%
20.24
+13.34%
17.86
Asset Impairment Charge
0.00
0.00
-100.00%
2.70
0.00
Deferred Tax
27.63
+262.70%
-16.98
-23.62%
-13.74
+12.79%
-15.75
Deferred Income Tax
27.63
+262.70%
-16.98
-23.62%
-13.74
+12.79%
-15.75
Operating Gains Losses
2.53
+214.52%
-2.21
-128.38%
7.79
+986.79%
-0.88
Gain Loss On Investment Securities
2.49
+189.26%
-2.79
-152.38%
5.33
+342.71%
-2.20
Change In Working Capital
-65.97
-353.50%
-14.55
+39.91%
-24.21
+24.76%
-32.18
Change In Receivables
-6.37
+70.62%
-21.67
+16.92%
-26.09
-157.46%
-10.13
Changes In Account Receivables
-6.37
+70.62%
-21.67
+16.92%
-26.09
-157.46%
-10.13
Change In Inventory
-21.06
+56.84%
-48.80
-2730.45%
-1.72
+85.32%
-11.75
Change In Prepaid Assets
-3.53
+67.09%
-10.73
-293.18%
-2.73
-47.14%
-1.85
Change In Payables And Accrued Expense
-4.56
-107.17%
63.56
+380.19%
13.24
+1898.51%
-0.74
Change In Payable
-4.56
-107.17%
63.56
+380.19%
13.24
+1898.51%
-0.74
Change In Account Payable
-4.56
-107.17%
63.56
+380.19%
13.24
+1898.51%
-0.74
Change In Other Working Capital
-24.84
-463.52%
6.83
+305.91%
-3.32
+27.14%
-4.55
Change In Other Current Liabilities
-5.61
-49.57%
-3.75
-4.49%
-3.59
-13.79%
-3.15
Investing Cash Flow
-70.33
+43.70%
-124.93
+80.75%
-649.12
-1880.40%
-32.78
Cash Flow From Continuing Investing Activities
-70.33
+43.70%
-124.93
+80.75%
-649.12
-1880.40%
-32.78
Net PPE Purchase And Sale
-34.88
+15.01%
-41.04
-7.53%
-38.17
-61.63%
-23.61
Purchase Of PPE
-34.88
+15.01%
-41.04
-7.53%
-38.17
-58.80%
-24.03
Sale Of PPE
—
0.00
0.00
-100.00%
0.42
Capital Expenditure
-37.13
+9.52%
-41.04
-7.53%
-38.17
-58.80%
-24.03
Net Investment Purchase And Sale
-28.84
-158.58%
49.23
+146.47%
-105.93
-1259.52%
-7.79
Purchase Of Investment
-119.13
-55.13%
-76.79
+46.88%
-144.56
-304.23%
-35.76
Sale Of Investment
90.29
-28.35%
126.02
+226.30%
38.62
+38.09%
27.97
Net Business Purchase And Sale
0.00
+100.00%
-129.00
+74.53%
-506.41
0.00
Purchase Of Business
0.00
+100.00%
-129.00
+74.53%
-506.41
0.00
Gain Loss On Sale Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
-2.25
0.00
0.00
—
Purchase Of Intangibles
-2.25
0.00
0.00
—
Net Other Investing Changes
-4.36
-5.88%
-4.12
-396.33%
1.39
+201.31%
-1.37
Financing Cash Flow
-67.42
+16.71%
-80.95
-117.83%
454.09
+1817.51%
-26.44
Cash Flow From Continuing Financing Activities
-67.42
+16.71%
-80.95
-117.83%
454.09
+1817.51%
-26.44
Net Issuance Payments Of Debt
5.99
-41.07%
10.17
-98.07%
526.34
+29653.17%
-1.78
Issuance Of Debt
6.22
-66.28%
18.43
-97.82%
845.00
0.00
Repayment Of Debt
-0.22
+97.30%
-8.26
+97.41%
-318.66
-17792.08%
-1.78
Long Term Debt Issuance
6.22
-66.28%
18.43
-97.82%
845.00
0.00
Long Term Debt Payments
-0.22
+97.30%
-8.26
+97.41%
-318.66
-17792.08%
-1.78
Net Long Term Debt Issuance
5.99
-41.07%
10.17
-98.07%
526.34
+29653.17%
-1.78
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
-75.59
+11.55%
-85.46
-46.98%
-58.14
-45.69%
-39.91
Common Stock Payments
-75.59
+11.55%
-85.46
-46.98%
-58.14
-45.69%
-39.91
Repurchase Of Capital Stock
-75.59
+11.55%
-85.46
-46.98%
-58.14
-45.69%
-39.91
Proceeds From Stock Option Exercised
2.85
+158.88%
-4.85
-144.19%
10.97
-29.91%
15.66
Net Other Financing Charges
-0.69
+15.81%
-0.82
+96.75%
-25.08
-6061.92%
-0.41
Changes In Cash
18.36
+144.68%
7.50
+165.13%
-11.52
-138.44%
29.96
Effect Of Exchange Rate Changes
0.21
+210.53%
-0.19
+32.62%
-0.28
-28.18%
-0.22
Beginning Cash Position
151.84
+5.06%
144.53
-7.55%
156.33
+23.50%
126.59
End Cash Position
170.41
+12.23%
151.84
+5.06%
144.53
-7.55%
156.33
Free Cash Flow
118.98
-30.96%
172.34
+18.58%
145.34
+123.09%
65.15
Interest Paid Supplemental Data
23.22
-13.40%
26.81
+52.57%
17.57
+481.31%
3.02
Income Tax Paid Supplemental Data
22.71
-43.37%
40.10
-18.16%
49.00
+10.26%
44.44
Earnings Losses From Equity Investments
0.00
-100.00%
0.57
-71.08%
1.98
+68.31%
1.18
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category